[Featured Stock] Voronoi Rises Over 5% on 'Clinical Trial Results Expectations'

The stock price of Voronoi, whose clinical results of several new drug candidates including the non-small cell lung cancer drug candidate 'VRN11' are highly anticipated, is on the rise.

As of 11:08 AM on the 12th, Voronoi was trading at 76,600 KRW, up 3,700 KRW (5.08%) from the previous trading day.

On the same day, Wihaeju, a researcher at Korea Investment & Securities, stated, "VRN11 has shown excellent efficacy in non-clinical animal models and has attracted market attention. It also has a relatively high brain penetration rate, indicating potential to effectively inhibit brain metastasis." He added, "According to the company, the goal is to present the interim results of Phase 1 clinical trials at the American Society of Clinical Oncology (ASCO) in June next year."

He continued, "There has also been progress in other research and development. The clinical trial plan for 'VRN10,' a human epidermal growth factor receptor 2 (HER2) targeted tyrosine kinase inhibitor (TKI), has been submitted to the regulatory authorities in Australia and Korea. Additionally, an option contract was signed with Anvia Therapeutics in the United States for the selection of a RIPK1 inhibitor candidate for the treatment of ulcerative colitis, psoriasis, and atopic dermatitis." He added, "As of the third quarter of this year, the company holds 63 billion KRW in cash. Considering that approximately 30 billion KRW is spent annually on selling and administrative expenses, the funds required for the next two years have been secured."

This content was produced with the assistance of AI translation services.